Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
Items 501–600 of 963
Asih, P. R., Chatterjee, P., Verdile, G., Gupta, V. B., Trengove, R. D., & Martins, R. N. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.29 · Cited by 25
Rosa-Neto, P., Hsiung, G.-Y., Masellis, M., & participants, O. B. O. T. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt223 · Cited by 23
“These methods constitute powerful means for in vivo detection of pathological Aβ1–42 aggregation and deposition in the brain tissue [2,13].”
Neuroimaging in Neurodegenerative Dementias
McGinnis, S. M. (2013) · Seminars in Neurology · doi:10.1055/s-0032-1331808 · Cited by 26
“59 d The United StatesFood and Drug Administration ’ s recent approval of fl orbetapir PET for clinical use stands to increase clinicians ’ diagnostic accuracy for AD (as con fi rmed pathologically), particularly in less-specialized settings, if used appropriately.”
Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
Zaretsky, D. V., Zaretskaia, M. V., Molkov, Y. I., & Initiative, A. D. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276933 · Cited by 27
In vitrobinding of [3H]PIB to human amyloid deposits of different types
Hellström‐Lindahl, E., Westermark, P., Antoni, G., & Estrada, S. (2013) · Amyloid · doi:10.3109/13506129.2013.860895 · Cited by 23
Carbonell, F., Charil, A., Zijdenbos, A. P., Evans, A. C., Bedell, B. J., & Initiative4, T. A. D. N. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.66 · Cited by 23
Enfermedad de Alzheimer. Guía de práctica clínica
Allegri, R., Arizaga, R. L., Bavec, C. V., Colli, L. P., Demey, I., Fernández, M. C., Frontera, S. A., Garau, M. L., Jiménez, J. J., Golimstok, Á., et al. (2011) · Neurología Argentina · doi:10.1016/s1853-0028(11)70026-x · Cited by 53
Jagust, W. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832d93c7 · Cited by 24
Biological changes associated with healthy versus pathological aging: A symposium review
Rajah, M. N., Bastianetto, S., Bromley‐Brits, K., Cools, R., D’Esposito, M., Grady, C. L., Poirier, J., Quirion, R., Raz, N., Rogaeva, E. A., et al. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.01.003 · Cited by 28
Yu, Y., Zhang, L., Li, C., Sun, X., Tang, D., & Shi, G. (2014) · Angewandte Chemie · doi:10.1002/ange.201405001 · Cited by 27
Parasagittal dural space hypertrophy and amyloid-β deposition in Alzheimer’s disease
Song, A. K., Hett, K., Eisma, J. J., McKnight, C. D., Elenberger, J., Stark, A. J., Kang, H., Yan, Y., Considine, C. M., Donahue, M. J., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad128 · Cited by 26
Unveiling Molecular Events in the Brain by Noninvasive Imaging
Klohs, J., & Rudin, M. (2011) · The Neuroscientist · doi:10.1177/1073858410383433 · Cited by 22
Azami, H., Mirjalili, M., Rajji, T. K., Wu, C., Humeau‐Heurtier, A., Jung, T., Wei, C.-S., Trinh, T.-T., & Liu, Y. (2025) · IEEE Journal of Selected Areas in Sensors · doi:10.1109/jsas.2025.3552546 · Cited by 23
“These markers have been found in postmortem brain tissue of patients with AD [22] and have been used to diagnose MCI and predict AD.”
Molecular Neuroimaging in Alzheimer's Disease
Matsuda, H., & Imabayashi, E. (2011) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.005 · Cited by 22
Diner, I., Dooyema, J. M., Gearing, M., Walker, L. C., & Seyfried, N. T. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00500 · Cited by 23
Minhas, D. S., Price, J. C., Laymon, C. M., Becker, C. R., Klunk, W. E., Tudorascu, D. L., Abrahamson, E. E., Hamilton, R. L., Kofler, J., Mathis, C. A., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.04.007 · Cited by 22
“In our investigations of the correspondence between [C-11]PiB PET and postmortem measures of Aβ pathology, we previously applied a modified form of the Meltzer PVC method to [C-11]PiB PET measures in two case reports [10, 16], but uncorrected [C-11]PiB measures were not examined.”
InfluentialSelf-citationCordero, I. R. G., Anastassiadis, C., Khoja, A. A., Morales‐Rivero, A., Thapa, S., Vasilevskaya, A., Davenport, C., Sumra, V., Couto, B., Multani, N., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26930 · Cited by 22
“30,32 Our results were also supported by the atrophy patterns that matched the expected AD pathology.”
Rinne, J. O., Frantzén, J., Leinonen, V., Lönnrot, K., Laakso, A., Virtanen, K. A., Solin, O. H., Kotkansalo, A., Koivisto, A. M., Sajanti, J., et al. (2013) · Neurodegenerative Diseases · doi:10.1159/000355256 · Cited by 24
Role of Hybrid Brain Imaging in Neuropsychiatric Disorders
Burhan, A. M., Marlatt, N. E., Palaniyappan, L. K., Anazodo, U., & Prato, F. S. (2015) · Diagnostics · doi:10.3390/diagnostics5040577 · Cited by 25
“This specific PET radiotracer can specifically bind to deposition in the human brain and is able to provide quantitative information on burden in vivo [64,65].”
BackgroundAdvances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use
George, N., Gean, E. G., Nandi, A., Фролов, Б. А., Zaidi, E., Lee, H., Brašić, J. R., & Wong, D. F. (2015) · CNS Drugs · doi:10.1007/s40263-015-0237-z · Cited by 24
“The most used 5-HT2A receptor radiotracers in research with potential for clinical applications are [(18)F]setoperone and [(18)F]altanserin [2, 63].”
BackgroundMethodChen, C.-J., Bando, K., Ashino, H., Taguchi, K., Shiraishi, H., Fujimoto, O., Kitamura, C., Matsushima, S., Fujinaga, M., Zhang, M., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.043 · Cited by 21
PET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 21
Postmortem Pittsburgh Compound B (PiB) Binding Increases with Alzheimer's Disease Progression
Beckett, T. L., Webb, R. L., Niedowicz, D. M., Holler, C. J., Matveev, S., Baig, I., LeVine, H., Keller, J. N., & Murphy, M. P. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120655 · Cited by 18
Ito, H., Shinotoh, H., Shimada, H., Miyoshi, M., Yanai, K., Okamura, N., Takano, H., Takahashi, H., Arakawa, R., Kodaka, F., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2620-7 · Cited by 22
“If the cerebral cortical uptake of [(11)C]PIB might be due to binding to both diffuse and dense-cored amyloid plaque [32], such regional differences in cerebral cortical uptake between [(11)C]PIB and [(18)F]FACT might be due to differences in regional distribution between diffuse and dense-cored amyloid plaque.”
BackgroundChinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies
Alausa, A. O., Ogundepo, S., Olaleke, B., Adeyemi, R. O., Olatinwo, M., & Ismail, A. (2021) · Chinese Medicine · doi:10.1186/s13020-020-00418-7 · Cited by 21
Seven-Tesla MRI and neuroimaging biomarkers for Alzheimer’s disease
Ali, R., Goubran, M., Choudhri, O., & Zeineh, M. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.9.focus15326 · Cited by 21
Patterns of Compensation and Vulnerability in Normal Subjects at Risk of Alzheimer's Disease
López, O. L., Becker, J. T., & Kuller, L. H. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129015 · Cited by 22
Higuchi, M., Maeda, J., Ji, B., Maruyama, M., Okauchi, T., Tokunaga, M., Ono, M., & Suhara, T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.01.003 · Cited by 20
“pound-B ([(11)C]PIB), which is the most intensively investigated amyloid radioligand due to its superior sensitivity and specificity in the detection of Aβ deposits besides the qualification of the aforementioned requirements [39,41,45,47].”
BackgroundCampbell, D. L., Kang, H., & Shokouhi, S. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s143307 · Cited by 20
[124I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease
Nguyen, G. A. H., Liang, C., & Mukherjee, J. (2022) · Molecules · doi:10.3390/molecules27144552 · Cited by 20
“The highly selective binding of [11C]PiB for insoluble amyloid plaques in the AD human brain was significantly correlated with post-mortem quantitative analyses [13].”
BackgroundNabuurs, R. J. A., Natté, R., de Ronde, F. M., Hegeman-Kleinn, I. M., Dijkstra, J., van Duinen, S. G., WEBB, A. G., Rozemüller, A. J. M., van Buchem, M. A., & van der Weerd, L. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122215 · Cited by 21
Relationship between β-amyloid and structural network topology in decedents without dementia
Jonkman, L. E., Steenwijk, M. D., Boesen, N., Rozemüller, A. J. M., Barkhof, F., Geurts, J. J. G., Douw, L., & van de Berg, W. D. J. (2020) · Neurology · doi:10.1212/wnl.0000000000009910 · Cited by 19
What amyloid ligands can tell us about molecular polymorphism and disease
LeVine, H., & Walker, L. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.019 · Cited by 20
Meyer, P. T., Frings, L., & Hellwig, S. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000107 · Cited by 21
Chakraborty, S., & Basu, S. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.11.061 · Cited by 19
Meyer, P., McSweeney, M., Gonneaud, J., & Villeneuve, S. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.001 · Cited by 22
“for the first clinical study using Pittsburgh Compound B (PiB), a tracer with high affinity and high selectivity for fibrillary Aβ in plaques.(16,17) To date, this remains the most successful and widely used tracer in research settings, often considered as the “gold standard” for imaging of Aβ pathology.”
MethodThe Role of Amyloid- and Tau PET in the New Era of Alzheimer Disease Therapies
Chiotis, K., Wang, Y., Joie, R. L., & Rabinovici, G. D. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268339 · Cited by 26
“The cerebellum, which shows minimal speci fi c binding because of its late involvement in A b pathology ( 15 ), is widely used as the reference region for scaling A b PET scans.”
Umlauf, A., Soontornniyomkij, B., Sundermann, E. E., Gouaux, B. D., Ellis, R. J., Levine, A. J., Moore, D. J., & Soontornniyomkij, V. (2019) · AIDS · doi:10.1097/qad.0000000000002336 · Cited by 18
“for this discrepancy is the lower sensitivity of PiB for detecting diffuse plaques (containing small amounts of fibrillar Ab [31]) as compared with cored plaques (composed predominantly of fibrillar Ab) [28,32].”
ResultAdvances in molecular imaging for the diagnosis of dementia
Okamura, N., Fodero‐Tavoletti, M. T., Kudo, Y., Rowe, C. C., Furumoto, S., Arai, H., Masters, C. L., Yanai, K., & Villemagne, V. L. (2009) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530050903133790 · Cited by 19
Boudjemeline, M., Hopewell, R., Rochon, P., Jolly, D., Hammami, I., Villeneuve, S., & Kostikov, A. P. (2017) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3569 · Cited by 18
“wileyonlinelibrar the first time, the Aβ plaques were visualized in the brains of living AD patients, and the correlation between amyloid deposition and radioactivity accumulation patterns was later validated by the autopsy in postmortem studies of typical AD brains.(8,9) By highlighting Aβ deposition, [(11)C]PiB prov…”
BackgroundWillroider, M., Roeber, S., Horn, A. K. E., Arzberger, T., Scheifele, M., Respondek, G., Sabri, O., Barthel, H., Patt, M., Mishchenko, O., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.684523 · Cited by 18
“A small subsample of six patients with AD showed that despite a good correlation between both techniques, the binding [pmol/mg] of the radioligand ([3H]PiB) to the FFPE samples was only 43 ± 24% of that observed in the corresponding frozen tissue samples (19).”
ResultSlee, M. G., Rainey‐Smith, S. R., Villemagne, V. L., Doecke, J. D., Sohrabi, H. R., Taddei, K., Ames, D. J., Doré, V., Maruff, P. T., Laws, S. M., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13556 · Cited by 18
Emerging Biomarkers in Cognition
Wicklund, M. R., & Petersen, R. C. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.006 · Cited by 19
Ellis, K. A., Rainey‐Smith, S. R., Rembach, A., Macaulay, S. L., Villemagne, V. L., & Aibl research group (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.870136 · Cited by 17
“…(Klunk et al., 2004; Rowe et al., 2007), correlating well with reductions in CSF A β 42 (Fagan et al., 2006) and AD histopathology (Bacskai et al., 2007; Ikonomovic et al., 2008; Leinonen et al., 2008), allowing earlier diagnosis of AD (Klunk et al., 2004; Rowe et al., 2007) and better…”
BackgroundIslam, A., Saito, T., Saido, T., & Ali, A. B. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.001 · Cited by 17
“This is also reported by multiple studies using immunohistochemical and PET imaging techniques ([46,70]; Ikonomovic et al. [80]).”
Current capacities for neuroimaging in the differential diagnosis of cognitive impairments
Emelin, А. Y., Odinak, M. M., Lobzin, V. Y., Vorobyev, S. V., & Kiselev, V. N. (2012) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2012-2509 · Cited by 18
Ji, B., Chen, C.-J., Bando, K., Ashino, H., Shiraishi, H., Sano, H., Kasahara, H., Minamizawa, T., YAMADA, K., Ono, M., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13293 · Cited by 17
“…agents including 11C-BF-227 and 18F-FACT, have been documented to bind to densecored, neuritic rather than non-classic plaques (Kudo et al. 2007; Ito et al. 2014), but the contrast for Ab lesions yielded by these ligands may not be sufficient for a robust quantification of these deleterious…”
Backgroundvon Reutern, B., Grünecker, B., Yousefi, B. H., Henriksen, G., Czisch, M., & Drzezga, A. E. (2013) · Molecular Imaging and Biology · doi:10.1007/s11307-013-0625-z · Cited by 20
Combination of dynamic 11C-PIB PET and structural MRI improves diagnosis of Alzheimer’s disease
Liu, L., Fu, L., Zhang, X., Zhang, J., Zhang, X., Xu, B., Tian, J., & Fan, Y. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.05.014 · Cited by 18
“As a PET tracer with an amyloid target, 11C-PIB has been demonstrated to bind specifically to extracellular and vascular fibrillar Aβ deposits in AD brains (Klunk et al., 2003; Ikonomovic et al., 2008; Rabinovici and Jagust, 2009).”
Fjell, A. M., & Walhovd, K. B. (2011) · The Neuroscientist · doi:10.1177/1073858410392586 · Cited by 19
Zhao, Q. X., Du, X., Chen, W., Zhang, T., & Xu, Z. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1216215 · Cited by 19
“Several studies have confirmed the correlation between PET/ CT measurements and histological evidence of deposited Aβ (Ikonomovic et al., 2008; Choi et al., 2012; Okazawa et al., 2020).”
BackgroundInitiative, A. D. N., Chiotis, K., Carter, S. F., Farid, K., Savitcheva, I., & Nordberg, A. K. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3115-5 · Cited by 17
“Autopsy studies of individuals who were scanned prior to death using PIB or Florbetapir have confirmed that both radiotracers bind selectively to fibrillar Aβ [6–9].”
BackgroundBa, M., Ng, K. P., Gao, X., Kong, M., Guan, L., Yu, L., & Initiative, T. A. D. N. (2018) · European Journal of Neurology · doi:10.1111/ene.13881 · Cited by 16
“In addition, amyloidPET is shown to be highly in agreement with histopathological amyloid aggregates [13].”
BackgroundSelvan, S. T., Ravichandar, R., Ghosh, K. K., Mohan, A., Mahalakshmi, P., Gulyás, B. Z., & Padmanabhan, P. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213659 · Cited by 17
Giacomucci, G., Mazzeo, S., Bagnoli, S., Casini, M., Padiglioni, S., Polito, C., Berti, V., Balestrini, J., Ferrari, C., Lombardi, G., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11010047 · Cited by 18
“However, despite the high concordance with histopathology [8,9], there are some caveats in the validation of the use of biomarkers.”
BackgroundShao, H., Okamura, N., Sugi, K., Furumoto, S., Furukawa, K., Tashiro, M., Iwata, R., Matsuda, H., Kudo, Y., Arai, H., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318754 · Cited by 17
Rinne, J. O., Suotunen, T., Rummukainen, J. K., Herukka, S., Nerg, O., Koivisto, A. M., Rauramaa, T. H., Någren, K., Hiltunen, M., Alafuzoff, I. I., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180645 · Cited by 17
“Our study is in agreement with the correlation between [ 11 C]PIB and the brain tissue A (cid:2) shown earlier in a small patient population [40, 30].”
Plasma-Enabled Carbon Nanostructures for Early Diagnosis of Neurodegenerative Diseases
Pineda, S., Han, Z., & Ostrikov, K. (2014) · Materials · doi:10.3390/ma7074896 · Cited by 17
“, Lewy bodies in the PD case [6] and Lewy-body dementia or plaques in the AD case [7,8]) is typically only possible post-mortem.”
BackgroundReiman, E. M., & Langbaum, J. B. S. (2009) · Imaging the Aging Brain · doi:10.1093/acprof:oso/9780195328875.003.0020 · Cited by 16
Seiffert, A. P., Gómez‐Grande, A., Villarejo‐Galende, A., González‐Sánchez, M., Bueno, H., Aguilera, E. J. G., & González, P. S. (2021) · Sensors · doi:10.3390/s21155182 · Cited by 16
“Validated Aβ-binding tracers are [11C]Pittsburgh compound-B (PiB) [3], [18F]florbetapir (FBP) [4], [18F]florbetaben (FBB) [5], and [18F]flutemetamol (FMM) [6].”
Abrahamson, E., Padera, R., Davies, J., Farrar, G., Villemagne, V., Dorbala, S., & Ikonomovic, M. (2022) · Amyloid: Journal of Protein Folding Disorders · doi:10.1080/13506129.2022.2141623 · Cited by 13
“We did not detect any endogenous fluorescence using our filter sets (see Methods), and specific fluorescence signal of cyano-labeled compounds and X-34 has been demonstrated in previous studies [51,55,56,70,76].”
BackgroundSelf-citationKarthivashan, G., & Kar, S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01957-5 · Cited by 17
Illustrated Neuropathologic Diagnosis of Alzheimer’s Disease
Doher, N., Davoudi, V., Magaki, S., Townley, R. A., Haeri, M., & Vinters, H. V. (2023) · Neurology International · doi:10.3390/neurolint15030054 · Cited by 16
Functional imaging of non-motor signs in Parkinson's disease
Ballanger, B., Poisson, A., Broussolle, E., & Thobois, S. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.11.008 · Cited by 18
Miki, T., Shimada, H., Kim, J., Yamamoto, Y., Sugino, M., Kowa, H., Heurling, K., Zanette, M., Sherwin, P. F., & Senda, M. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1154-7 · Cited by 17
Molecular imaging: What is right and what is an illusion?
Klunk, W. E. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.004 · Cited by 15
“Within a couple of years, postmortem correlative data began to appear that showed gray matter PiB retention correlated closely with Ab load measured immunohistochemically and biochemically [7,8].”
Self-citationBarć, K., & Kuźma‐Kozakiewicz, M. (2019) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2019.0013 · Cited by 17
“Aβ tracers A retention of Aβ PET tracers highly correlates with brain biopsy findings [40, 41].”
BackgroundBao, Y., Chau, A. C. M., Chiu, P. K., Shea, Y. F., Kwan, J. S. K., Chan, F. H. W., & Mak, H. K. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200890 · Cited by 15
“False-positive cases had mainly diffuse amyloid plaques, i.e., plaques without neuritic pathology or dense amyloid core [38, 39].”
Mi, Z., Abrahamson, E. E., Ryu, A. Y., Malek‐Ahmadi, M. H., Kofler, J., Fish, K. N., Sweet, R. A., Villemagne, V. L., Schneider, J. A., Mufson, E. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221063 · Cited by 15
Self-citationPascoal, T. A., Therriault, J., Mathotaarachchi, S. S., Kang, M. S., Shin, M., Benedet, A. L., Chamoun, M., Tissot, C., Lussier, F. Z., Mohaddes, S., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12037 · Cited by 18
Imaging and biomarkers for Alzheimer's disease
Allan, C. L., Sexton, C. E., Welchew, D., & Ebmeier, K. P. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.006 · Cited by 22
Doi, H., Inamizu, S., Saitoh, B., Murai, H., Araki, T., & Kira, J. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3747 · Cited by 16
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 15
“Strong concordance of in vivo PiB retention with region-matched quantitative analyses of amyloid plaques in post-mortem tissue of end-of-life subjects supported the validity of PET imaging, and thus justified its clinical use (Ikonomovic et al. 2008).”
BackgroundTo donate, or not to donate, that is the question: Latino insights into brain donation
Paredes, A. M., Guareña, L. A., Stickel, A. M., Schairer, C. E., & González, H. M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12755 · Cited by 14
Mrđenović, D., Combes, B. F., Ni, R., Zenobi, R., & Kumar, N. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00607 · Cited by 16
Biomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 25
Bielekova, B., & Pranzatelli, M. R. (2017) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2017.08.001 · Cited by 15
Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI
Visser, P. J., & Knopman, D. S. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b61b5d · Cited by 14
Is Olfactory Epithelium Biopsy Useful for Confirming Alzheimer’s Disease?
Godoy, M. D. C. L., Fornazieri, M. A., Doty, R. L., Pinna, F. D. R., Farfel, J. M., dos Santos, G. B., Molina, M., Ferretti‐Rebustini, R. E. D. L., Leite, R. E. P., Suemoto, C. K., et al. (2018) · Annals of Otology Rhinology & Laryngology · doi:10.1177/0003489418814865 · Cited by 14
Sachdev, P. S. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000577 · Cited by 13
Comparison Between 18F-Florapronol and 18F-Florbetaben Imaging in Patients With Cognitive Impairment
Baik, K., Jeon, S., Park, M., Lee, Y., Lee, P. H., Sohn, Y. H., & Ye, B. S. (2023) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.0207 · Cited by 14
The role of PET quantification in neurological imaging: FDG and amyloid imaging in dementia
Herholz, K. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0073-z · Cited by 14
Geriatric Medicine, Japanese Alzheimer's Disease Neuroimaging Initiative and Biomarker Development
Arai, H., Okamura, N., Furukawa, K., & Kudo, Y. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.221.87 · Cited by 14
“The [(11)C]PIB retention in the neocortical areas is correlated with the Aβ plaque load (Bacskai et al. 2007; Ikonomovic et al. 2008) with an inverse relation to CSF Aβ42 levels (Fagan et al.”
BackgroundOmachi, Y., Ito, K., Arima, K., Matsuda, H., Nakata, Y., Sakata, M., Sato, N., Nakagome, K., & Motohashi, N. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12326 · Cited by 13
Automatic segmentation of amyloid plaques in MR images using unsupervised support vector machines
Iordanescu, G., Venkatasubramanian, P. N., & Wyrwicz, A. M. (2011) · Magnetic Resonance in Medicine · doi:10.1002/mrm.23138 · Cited by 13
Gertz, H., & Kurz, A. (2011) · Der Nervenarzt · doi:10.1007/s00115-010-3213-3 · Cited by 16
Studying Arterial Stiffness Using High-Frequency Ultrasound in Mice with Alzheimer Disease
Huang, C.-C., Cheng, H.-F., Zhu, B.-P., Chen, P., Beh, S. T., Kuo, Y., & Huang, C. (2017) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2017.04.029 · Cited by 13
Sheikh‐Bahaei, N., Manavaki, R., Sajjadi, S. A., Priest, A. N., O'Brien, J. T., & Gillard, J. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180443 · Cited by 13
Senda, M., Brooks, D. J., Farrar, G., Somer, E. J., Paterson, C. L., Sasaki, M., & McParland, B. J. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-0986-2 · Cited by 14
Concordance Between 11 C-PIB-PET and Clinical Diagnosis in a Memory Clinic
Patricio, C. M., Cohen, G., Russo, J., Suarez, M. F., Nahas, F., Russo, G., Claudio, W., Santiago, P., Leonardo, T., Jorge, C., et al. (2015) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515576387 · Cited by 13
Booij, J., Arbizu, J., Darcourt, J., Hesse, S., Nobili, F. M., Payoux, P., Pappatà, S., Tatsch, K., Walker, Z., & Pagani, M. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2415-x · Cited by 14
“Importantly, several studies confirmed that the in vivo observations with [C]PiB PET are highly correlated with post-mortem assessment of amyloid pathology [12–14].”
BackgroundTwo decades of [11C]PiB synthesis, 2003-2023: a review
Myburgh, P. J. (2024) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/adsk6584 · Cited by 12
Youn, Y. C., Kim, H. R., Shin, H.-W., Jeong, H.-B., Han, S., Pyun, J., Ryoo, N., Park, Y. H., & Kim, S. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-02024-z · Cited by 12
“Some early indications were that Pittsburgh compound B (PIB), a PET tracer, binds to neuritic plaques but not to diffuse plaques [24].”
BackgroundStudy of amyloid-β peptide functional brain networks in AD, MCI and HC
Jiang, J., Duan, H., Huang, Z., Yu, Z., & Initiative, T. A. D. N. (2015) · Bio-Medical Materials and Engineering · doi:10.3233/bme-151525 · Cited by 12
“PiB-PET images (HC=15, AD=11) 11 ROIs are identified as A ROIs, including CER, SWM, PON, CAU, SMC, FRT, PCG, LTC, MTC, and OCC [5].”
BackgroundResultTechnical aspects of amyloid imaging for Alzheimer's disease
Edison, P., Hinz, R., & Brooks, D. J. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt87 · Cited by 13
“A patient who underwent postmortem neuropathological examinations 10 months after [11C]PIB PET imaging demonstrated that in vivo retention corre lated directly with postmortem quantifi cation of PIB and Aβ plaque load but not with neurofi brillary tangle or other neurofi brillary pathology [17].”
BackgroundAmyloid deposition and CBF patterns predict conversion of mild cognitive impairment to dementia
Kikukawa, T., Abe, T., Ataka, S., Saito, H., Hasegawa, I., Mino, T., Takeuchi, J., Kawabe, J., Wada, Y., Watanabe, Y., et al. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3477-0 · Cited by 13
Community perceptions related to brain donation: Evidence for intervention
Striley, C. W., Milani, S. A., Kwiatkowski, E. K., DeKosky, S. T., & Cottler, L. B. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.005 · Cited by 12
Self-citationChang, Y. Z., Liu, J., Wang, L. Y., Li, X., Wang, Z., Lin, M., Jin, W., Zhu, M., & Xu, B. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.721780 · Cited by 15
Amyloid PET in neurodegenerative diseases with dementia
Camacho, V., Gómez‐Grande, A., Sopena, P., Solís, D. G., Río, M. G., Lorenzo‐Bosquet, C., Rubí, S., & Arbizu, J. (2018) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2018.04.003 · Cited by 16
Amyloid imaging in Alzheimer's disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0507-3 · Cited by 12
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.